Abstract:Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several are under development. While effective for some cancers, toxicities remain a limitation. The most common toxicities, i.e. cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), are well described. With increasing utilization, providers worldwide are reporting on other emergent, and often complicated toxicities. Given the evolving toxicity profiles and urgent need to catalogue these emerging and emergent CAR T toxicities and describe management approaches, the American Society of Hematology Subcommittee on Emerging Gene and Cell Therapies organized the first Scientific Workshop on CAR T cell toxicities during the annual society meeting. The workshop functioned to 1) aggregate reports of CAR T emergent toxicities, including movement disorders after BCMA CAR T, coagulation abnormalities, and prolonged cytopenias; 2) disseminate bedside to bench efforts elucidating pathophysiological mechanisms of CAR-T toxicities, including the intestinal microbiota and systemic immune dysregulation; and 3) highlight gaps in the availability of clinical tests such as cytokine measurements, which could be utilized to expand our knowledge around the monitoring of toxicities. Key themes emerged. First, while clinical manifestations may develop before the pathophysiologic mechanisms are understood, these must be studied to aid in the detection and prevention of such toxicities. Second, systemic immune dysregulation appears central to these emergent toxicities and research is needed to elucidate links between tumor, CAR T, and microbiota. Finally, there was consensus around an urgency to create a repository to capture emergent CAR-T toxicities and the real-world management.

Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy

Toxicity and management in CAR T-cell therapy

Current understanding and management of CAR T cell-associated toxicities

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Mechanisms and management of CAR T toxicity

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Toxicity of Chimeric Antigen Receptor T Cells and Its Management

CAR T cell Toxicities: Bedside to Bench – How Novel Toxicities Inform Laboratory Investigations

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

Evolving strategies for addressing CAR T-cell toxicities

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

Reactions Related to CAR-T Cell Therapy

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances